The oral GLP-1 segment is entering a pivotal stage, with major growth anticipated from 2026 onward. Patient preference for oral pills over injectables is strong, making ease of use a key driver for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback